Point72 Asset Management L.P. decreased its position in NxStage Medical, Inc. (NASDAQ:NXTM) by 69.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 81,748 shares of the medical device company’s stock after selling 185,152 shares during the quarter. Point72 Asset Management L.P. owned about 0.12% of NxStage Medical worth $2,256,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also recently made changes to their positions in the company. Prudential Financial Inc. purchased a new stake in NxStage Medical in the 3rd quarter valued at about $202,000. Amalgamated Bank grew its holdings in shares of NxStage Medical by 7.1% during the 2nd quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock worth $210,000 after purchasing an additional 553 shares during the period. Koch Industries Inc. purchased a new stake in shares of NxStage Medical during the 2nd quarter worth about $227,000. Suntrust Banks Inc. lifted its position in NxStage Medical by 2.3% during the 2nd quarter. Suntrust Banks Inc. now owns 9,480 shares of the medical device company’s stock worth $237,000 after acquiring an additional 209 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its position in NxStage Medical by 217.0% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,676 shares of the medical device company’s stock worth $243,000 after acquiring an additional 6,624 shares in the last quarter. 85.35% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts recently commented on the company. Zacks Investment Research raised NxStage Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. Northland Securities reaffirmed a “hold” rating and issued a $30.00 target price on shares of NxStage Medical in a research report on Wednesday, November 8th. Finally, Canaccord Genuity reaffirmed a “hold” rating and issued a $30.00 target price on shares of NxStage Medical in a research report on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating and nine have given a hold rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $30.25.
Shares of NxStage Medical, Inc. (NXTM) traded up $0.10 during mid-day trading on Friday, reaching $24.77. The company had a trading volume of 237,767 shares, compared to its average volume of 393,389. NxStage Medical, Inc. has a fifty-two week low of $20.45 and a fifty-two week high of $30.80. The company has a market capitalization of $1,630.00, a PE ratio of -117.95 and a beta of -0.08.
In other news, SVP Winifred L. Swan sold 3,500 shares of the company’s stock in a transaction on Friday, October 20th. The stock was sold at an average price of $27.50, for a total transaction of $96,250.00. Following the completion of the sale, the senior vice president now directly owns 15,270 shares of the company’s stock, valued at $419,925. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 10,500 shares of company stock valued at $275,030. 4.70% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: “Point72 Asset Management L.P. Has $2.26 Million Stake in NxStage Medical, Inc. (NXTM)” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://ledgergazette.com/2018/01/13/nxstage-medical-inc-nxtm-shares-sold-by-point72-asset-management-l-p.html.
NxStage Medical Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.